Overview

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Status:
Recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
Cancer drugs which target the effects of abnormal gene changes are called 'targeted therapies'. This study, called PM.1 or CAPTUR, will include some targeted therapies that are currently available. The purpose of this study is to find out what are the effects on a patient and their cancer when they are given a targeted therapy drug that is specific to an abnormal gene change in their cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Canadian Cancer Trials Group
Collaborators:
AstraZeneca
Boehringer Ingelheim
Bristol-Myers Squibb
Hoffmann-La Roche
Pfizer
Treatments:
Axitinib
Crizotinib
Dasatinib
Ipilimumab
Nivolumab
Olaparib
Palbociclib
Pertuzumab
Sunitinib
Trastuzumab
Vemurafenib